ati-1013
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2025 (NCT07215923)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- nicotineINHIBITOR
nicotine inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07215923 | Phase 1 | Oct 31, 2025 | Antidote Therapeutics, Inc, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antidote Therapeutics, Inc | For profit | 1 | 1 | 1 | 2025 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2025 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1